These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 35278641)

  • 1. Falnidamol and cisplatin combinational treatment inhibits non-small cell lung cancer (NSCLC) by targeting DUSP26-mediated signal pathways.
    Cui Z; Li D; Zhao J; Chen K
    Free Radic Biol Med; 2022 Apr; 183():106-124. PubMed ID: 35278641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reelin Promotes Cisplatin Resistance by Induction of Epithelial-Mesenchymal Transition via p38/GSK3β/Snail Signaling in Non-Small Cell Lung Cancer.
    Li JM; Yang F; Li J; Yuan WQ; Wang H; Luo YQ
    Med Sci Monit; 2020 Aug; 26():e925298. PubMed ID: 32764530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ginkgetin derived from Ginkgo biloba leaves enhances the therapeutic effect of cisplatin via ferroptosis-mediated disruption of the Nrf2/HO-1 axis in EGFR wild-type non-small-cell lung cancer.
    Lou JS; Zhao LP; Huang ZH; Chen XY; Xu JT; Tai WC; Tsim KWK; Chen YT; Xie T
    Phytomedicine; 2021 Jan; 80():153370. PubMed ID: 33113504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long intergenic noncoding RNA GAS5 reduces cisplatin-resistance in non-small cell lung cancer through the miR-217/LHPP axis.
    Yang X; Meng L; Zhong Y; Hu F; Wang L; Wang M
    Aging (Albany NY); 2021 Jan; 13(2):2864-2884. PubMed ID: 33418541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human non‑small lung cancer cells by regulating the YAP pathway.
    Jin D; Wu Y; Shao C; Gao Y; Wang D; Guo J
    Oncol Rep; 2018 Aug; 40(2):609-620. PubMed ID: 29901163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
    He Y; Xie H; Yu P; Jiang S; Wei L
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isovitexin potentiated the antitumor activity of cisplatin by inhibiting the glucose metabolism of lung cancer cells and reduced cisplatin-induced immunotoxicity in mice.
    Chen RL; Wang Z; Huang P; Sun CH; Yu WY; Zhang HH; Yu CH; He JQ
    Int Immunopharmacol; 2021 May; 94():107357. PubMed ID: 33715980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
    Xiao XH; He SY
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis.
    Shi Y; Ma IT; Patel RH; Shang X; Chen Z; Zhao Y; Cheng J; Fan Y; Rojas Y; Barbieri E; Chen Z; Yu Y; Jin J; Kim ES; Shohet JM; Vasudevan SA; Yang J
    Cell Death Dis; 2015 Aug; 6(8):e1841. PubMed ID: 26247726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circ_0000079 Decoys the RNA-Binding Protein FXR1 to Interrupt Formation of the FXR1/PRCKI Complex and Decline Their Mediated Cell Invasion and Drug Resistance in NSCLC.
    Chen C; Zhang M; Zhang Y
    Cell Transplant; 2020; 29():963689720961070. PubMed ID: 32951448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis.
    Huang Q; Xing S; Peng A; Yu Z
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
    Cai Y; Dong ZY; Wang JY
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer.
    Chen Y; Zhou H; Yang S; Su D
    Cell Biochem Funct; 2021 Mar; 39(2):277-286. PubMed ID: 32815556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
    Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
    Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-induced antizyme inhibitors 2 regulates cisplatin resistance through epithelia-mesenchymal transition pathway in non-small cell lung cancer.
    Shi Q; Chen Q; Zhou Z; Zheng X; Huang X; Fang M; Hu Y; Song L; Yang H; Chen Q
    Pulm Pharmacol Ther; 2021 Aug; 69():102048. PubMed ID: 34082109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pentraxin 3 acts as a functional effector of Akt/NF-κB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer.
    Li Y; Song X; Niu J; Ren M; Tang G; Sun Z; Kong F
    Arch Biochem Biophys; 2021 Apr; 701():108818. PubMed ID: 33617838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1.
    Zhang H; Hu B; Wang Z; Zhang F; Wei H; Li L
    Cancer Chemother Pharmacol; 2017 Nov; 80(5):973-984. PubMed ID: 28956120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
    Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
    Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. USP3 promotes cisplatin resistance in non-small cell lung cancer cells by suppressing ACOT7-regulated ferroptosis.
    Tao R; Liu Z; Zhang Z; Zhang Z
    Anticancer Drugs; 2024 Jul; 35(6):483-491. PubMed ID: 38502867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J.
    Shi L; Xu Z; Wu G; Chen X; Huang Y; Wang Y; Jiang W; Ke B
    BMC Cancer; 2017 Feb; 17(1):138. PubMed ID: 28202053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.